scholarly journals Human islet transplantation network for the treatment of Type I diabetes: first data from the Swiss-French GRAGIL consortium (1999-2000)

Diabetologia ◽  
2001 ◽  
Vol 44 (7) ◽  
pp. 859-864 ◽  
Author(s):  
C. Toso ◽  
L. Kessler ◽  
A. Penfornis ◽  
F. Bayle ◽  
C. Thivolet ◽  
...  
Keyword(s):  
Islet Transplantation ◽  
Type I Diabetes ◽  
Human Islet ◽  
Type I ◽  
Human Islet Transplantation

Human Islet Transplantation: Current Status and Future Direction

2013 ◽  
Vol 5 (3) ◽  
pp. 156-161
Author(s):  
James McGarrigle ◽  
Jose Oberholzer
Keyword(s):  
Islet Transplantation ◽  
Human Islet ◽  
Current Status ◽  
Human Islet Transplantation ◽  
Future Direction

Editorial (Hot Topic: Current Applications of Micro and Nano Technology in Human Islet Transplantation)

2013 ◽  
Vol 5 (3) ◽  
pp. 155-155
Author(s):  
James McGarrigle ◽  
Jose Oberholzer
Keyword(s):  
Islet Transplantation ◽  
Human Islet ◽  
Nano Technology ◽  
Human Islet Transplantation

Pancreatic islet transplantation as a therapy for Type I diabetes

Impact ◽  
2019 ◽  
Vol 2019 (2) ◽  
pp. 15-17
Author(s):  
Robert Possee
Keyword(s):  
Islet Transplantation ◽  
Pancreatic Islet ◽  
Type I Diabetes ◽  
Type I ◽  
Pancreatic Islet Transplantation

scholarly journals Tolerance and pancreatic islet transplantation

2001 ◽  
Vol 356 (1409) ◽  
pp. 759-765 ◽  
Author(s):  
Luca Inverardi ◽  
Camillo Ricordi
Keyword(s):  
Diabetes Mellitus ◽  
Islet Transplantation ◽  
Type I Diabetes ◽  
Immunological Tolerance ◽  
Type I Diabetes Mellitus ◽  
Current Status ◽  
Type I ◽  
Pancreatic Islet Transplantation ◽  
Term Survival

Islet transplantation holds renewed promise as a cure for type I diabetes mellitus. Results of recent clinical trials have shown remarkable success, and have reignited universal optimism for this procedure. In spite of this success, the need for life–long immunosuppression of the recipient still limits islet transplantation to patients with poorly controlled diabetes or to those requiring kidney transplantation. It is obvious that the achievement of immunological tolerance would broaden the indication for islet transplantation to a much larger cohort of patients with type I diabetes mellitus, most likely preventing long–term complications and contributing to a much improved quality of life. Increased understanding of the basic mechanisms of tolerance induction has resulted in the implementation of numerous experimental approaches to achieve long–term survival of islet grafts in the absence of chronic immunosuppression. In this brief review we will attempt to summarize the current status of research and knowledge.

Engraftment Site and Effectiveness of the Pan-Caspase Inhibitor F573 to Improve Engraftment in Mouse and Human Islet Transplantation in Mice

2017 ◽  
Vol 101 (10) ◽  
pp. 2321-2329 ◽  
Author(s):  
Andrew R. Pepper ◽  
Antonio Bruni ◽  
Rena Pawlick ◽  
John Wink ◽  
Yasmin Rafiei ◽  
...  
Keyword(s):  
Islet Transplantation ◽  
Human Islet ◽  
Caspase Inhibitor ◽  
Human Islet Transplantation

Pancreas and islet transplantation in the treatment of type I diabetes

2000 ◽  
pp. 139-143
Author(s):  
X. Martin ◽  
P. Petruzzo ◽  
N. Lefrancois ◽  
L. Badet ◽  
J. M. Dubernard
Keyword(s):  
Islet Transplantation ◽  
Type I Diabetes ◽  
Type I

Cytokine transcripts in peripheral blood cells during immunosuppressive induction therapy in allogeneic human islet transplantation

1997 ◽  
Vol 29 (4) ◽  
pp. 2154 ◽  
Author(s):  
A. El-Ouaghlidi ◽  
H. Jahr ◽  
G. Pfeiffer ◽  
B.J. Hering ◽  
K. Federlin ◽  
...  
Keyword(s):  
Islet Transplantation ◽  
Induction Therapy ◽  
Peripheral Blood ◽  
Blood Cells ◽  
Human Islet ◽  
Peripheral Blood Cells ◽  
Human Islet Transplantation

scholarly journals Porous Scaffolds Support Extrahepatic Human Islet Transplantation, Engraftment, and Function in Mice

2013 ◽  
Vol 22 (5) ◽  
pp. 811-819 ◽  
Author(s):  
Romie F. Gibly ◽  
Xiaomin Zhang ◽  
William L. Lowe ◽  
Lonnie D. Shea
Keyword(s):  
Islet Transplantation ◽  
Human Islet ◽  
Porous Scaffolds ◽  
Human Islet Transplantation ◽  
And Function

VP40 Comprehensive Evaluation Of Islet Transplantation For Type I Diabetes

2017 ◽  
Vol 33 (S1) ◽  
pp. 166-167
Author(s):  
Danni Chen ◽  
Kun Xiong ◽  
Di Xue
Keyword(s):  
Cost Effectiveness ◽  
Islet Transplantation ◽  
Type I Diabetes ◽  
Insulin Dose ◽  
Cochrane Library ◽  
Type I ◽  
Islet Graft ◽  
Pancreatic Islet Transplantation ◽  
Insulin Independence

INTRODUCTION:Despite several therapeutic options existing for the patients with type I diabetes, the patients are still at high risk for severe acute and chronic complications (1). Pancreatic islet transplantation is a promising therapy to achieve good glycemic control with no or little additional insulin (2). This study was to evaluate the effectiveness, safety, economics and social ethics of islet transplantation (IT) for the patients with type I diabetes.METHODS:We searched PubMed, Cochrane Library, CNKI and CBM to retrieve eligible literatures. The values of H1bAc before and after transplantation, the rates of insulin independence and functional islet graft at the last follow-up, and the insulin dose per patient-day were analyzed. Descriptive statistics, t tests and random effects meta-analyses were used in the study.RESULTS:Totally 21 original papers with 488 cases from 9 different countries were reviewed and analyzed. The studies showed that the H1bAc was decreased from 7.7 percent (95 percent Confidence Interval, CI: 7.4, 8.1) before IT to 6.2 percent (95 percent CI: 5.9, 6.4) after IT. At the last follow-up, the rate of insulin independence was 48.96 percent (95 percent CI: 31.32, 66.73) and the rate of functional islet graft was 65.79 percent (95 percent CI: 47.06, 82.21). The daily insulin requirement dropped from 0.52U/kg/d to 0.21 U/kg/d. The main adverse events of islet transplantation were bleeding (7.01 percent) and the complications related to immunosuppression therapy (6.37 percent), but they were less than those of whole pancreas transplantation.Another study with a 20-year follow-up also showed that the cost-effectiveness of islet transplantation (USD47,800 per QALY) was better than that of insulin therapy (USD71,000 per QALY). In spite of the better evidences of islet transplantation, the insufficient organ donation and issues of cell purification and immunological rejection limited islet transplantation's widespread utilization (1).CONCLUSIONS:The islet transplantation therapy for the patients with type I diabetes has a potential to achieve insulin independence and better cost-effectiveness, and is relatively safe. But there are some obstacles for its wide utilization.

scholarly journals Islet Cell Hormonal Responses to Hypoglycemia After Human Islet Transplantation for Type 1 Diabetes

Diabetes ◽  
2005 ◽  
Vol 54 (11) ◽  
pp. 3205-3211 ◽  
Author(s):  
M. R. Rickels ◽  
M. H. Schutta ◽  
R. Mueller ◽  
J. F. Markmann ◽  
C. F. Barker ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Islet Transplantation ◽  
Islet Cell ◽  
Human Islet ◽  
Hormonal Responses ◽  
Human Islet Transplantation
Sign in / Sign up

Export Citation Format

Share Document